Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01107431 · ClinicalTrials.gov registry record · NA
Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin
A NA study of PreDiabetes, sponsored by Integrative Health Technologies.
- Completed
- Registry status
- NA
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT01107431: Completed NA study of PreDiabetes, sponsored by Integrative Health Technologies.
NCT01107431 is a NA study of PreDiabetes that has completed, run by Integrative Health Technologies. The registered enrollment target is 70 participants, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01107431, a NA study of PreDiabetes, has completed, sponsored by Integrative Health Technologies.
- COMPLETED
- Registry status
- NA
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This study was designed to examine changes in capillary blood glucose and venous insulin levels after a 70 gram oral sucrose challenge with and without simultaneous consumption of a dietary supplement containing L-Arabinose and a patented version of chromium (LA-Cr).
Primary Outcome
Finger-stick glucose measurements taken every 15 or 30 minutes after taking a 70 gram sucrose challenge with and without the dietary supplement
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT L-Arabinose and Chromium
- DIETARY_SUPPLEMENT Sucrose without dietary Supplement
Study Locations (1)
Texas
- Integrative Health Technologies - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2008-12 |
| Est. Completion | 2009-12 |
| Phase | NA |
What the finished NCT01107431 record still lists
NCT01107431 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 701-participant average among 149 other PreDiabetes trials with a reported enrollment target (90% lower).
The record links to 1 condition, with PreDiabetes appearing as the primary indexed condition, and to 2 interventions - of which L-Arabinose and Chromium is the first listed.
NCT01107431 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01107431 about?
NCT01107431 is a clinical study titled "Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin". This study was designed to examine changes in capillary blood glucose and venous insulin levels after a 70 gram oral sucrose challenge with and without simultaneous consumption of a dietary supplement containing L-Arabinose and a patented version of chromium (LA-Cr).
What is the current status of trial NCT01107431?
This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2008-12. Estimated completion is 2009-12.
What conditions does trial NCT01107431 study?
This clinical trial studies the following conditions: PreDiabetes.
What interventions are being tested in trial NCT01107431?
The interventions under investigation include: L-Arabinose and Chromium (DIETARY_SUPPLEMENT), Sucrose without dietary Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01107431?
This trial is sponsored by Integrative Health Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01107431 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PreDiabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01107431's enrollment target sits among peer trials
70 79th of 149 higher than 68 of 149 other PreDiabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PreDiabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
-
Cleaner Air for Lower Cardiometabolic Risk
RECRUITING · NA
-
Strategies for Implementing a Postpartum Lifestyle Intervention in WIC Clinics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia